Skip to main content

A Phase 2 Open-Label Trial to Assess the Efficacy and Safety of KRN23, an Antibody to FGF23, in Subjects with Tumor-Induced Osteomalacia (TIO) or Epidermal Nevus Syndrome (ENS)

Clinical Trial Grant
Duke Scholars

Administered By

School of Medicine

Awarded By

Ultragenyx Pharmaceutical

Start Date

July 15, 2015

End Date

November 30, 2019
 

Administered By

School of Medicine

Awarded By

Ultragenyx Pharmaceutical

Start Date

July 15, 2015

End Date

November 30, 2019